Jeffry B. Lansman (born 1951, in Miami Beach, Florida) is an American neuroscientist, professor emeritus of cellular and molecular pharmacology at the School of Medicine of the University of California, San Francisco, and member of UCSF's Weill Institute for Neurosciences and Cardiovascular Research Institute. He is also Senior Scientific Advisor to Cardio AI, a precision cardiovascular care company advancing AI-enhanced rapid diagnosis and treatment of cardiovascular disease.
Lansman studied biology at Purchase College (Bachelor of Science), and Tufts University (Master of Science) and subsequently received a Ph.D. in physiology and biophysics at UCLA School of Medicine under Susumu Hagiwara. He went on to complete postdoctoral training at the Yale School of Medicine and the Physiological Laboratory at the University of Cambridge.
He joined the faculty of the Department of Pharmacology at UCSF School of Medicine as an assistant professor where he received tenure as associate professor and then became professor of cellular & molecular pharmacology.[1]
Lansman is known for his research on calcium channels in nerves and muscles and their role in normal physiology and in disease. His early work on marine invertebrates identified the ion channels that produce the rhythmic beating of the heart. While working at Yale School of Medicine with Richard W. Tsien and Peter Hess, he discovered the L-type and T-type channels in heart muscle that control heart rate and contractility. He subsequently identified ion channels that transduce mechanical forces into the entry of calcium into blood vessels and skeletal muscle and contribute to vascular regulation and muscle degeneration in muscular dystrophy.
In 2017, he founded Turex Marine Biopharma to explore marine biomes and discover new drugs for treating neurodegenerative diseases.